Publication of Annual Report and Accounts

RNS Number : 0186C
MaxCyte, Inc.
16 June 2021





MaxCyte, Inc.

("MaxCyte" or the "Company")


Publication of Annual Report and Accounts


Gaithersburg, Maryland - 16 June 2021: MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announces that it has published its Annual Report and Accounts for the year ending 31 December 2020.


The Annual Report is available to view on the Company's website at and printed copies of the reports have been posted to those shareholders who have elected to continue to receive paper communications.




About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialisation. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centres focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted pre-clinical and clinical licences to academic and industry customers covering over an estimated 140 programmes, of which an estimated 100 programmes are for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit



For further information please contact:


MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

+1 301 944 1660


Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden


+44 (0)20 7886 2500


Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith



+44 (0)20 7260 1000

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams  

+44 (0) 20 7710 7600


Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh


+44 (0)203 709 5700


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100